PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacterial-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
PHAXIAM is listed on the Nasdaq Capital Market in the United States (ticker: PHXM) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

Biotechnology

Life Sciences

Pharmaceutical

PHAXIAM Therapeutics

Thibaut du Fayet

Jonathan Blachier

Daniel Cole

Anne-Cécile Fumey

Frederic Mathat

Elizabeth Todd

Jonathan Barber

Jerome Bailly

Iman El-Hariry

The Leadership Team at PHAXIAM Therapeutics is responsible for setting the strategic direction, overseeing daily operations, and ensuring regulatory compliance as the company develops innovative phage-based treatments for resistant bacterial infections. This team drives corporate development, quality assurance, human resources, and medical strategy, while managing financial and operational activities to align with PHAXIAM's goals and regulatory standards.

Leadership Team

Research and Development Team

Regulatory Affairs Team

Leadership Team

About

Team members

Other teams at PHAXIAM Therapeutics

Research and Development Team

Regulatory Affairs Team